ID   WM9 R
AC   CVCL_E3AH
RX   PubMed=39175042;
CC   Selected for resistance to: ChEBI; CHEBI:90851; Cobimetinib (Cotellic).
CC   Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Left axillary lymph node; UBERON=UBERON_0001097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6806 ! WM9
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 10-09-24; Version: 1
//
RX   PubMed=39175042; DOI=10.1186/s12964-024-01788-3; PMCID=PMC11342534;
RA   Kot M., Simiczyjew A., Wadzynska J., Zietek M., Matkowski R.A.,
RA   Nowak D.;
RT   "Characterization of two melanoma cell lines resistant to BRAF/MEK
RT   inhibitors (vemurafenib and cobimetinib).";
RL   Cell Commun. Signal. 22:410.1-410.21(2024).
//